<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112645</url>
  </required_header>
  <id_info>
    <org_study_id>PSCI-20615</org_study_id>
    <secondary_id>CDR0000430441</secondary_id>
    <nct_id>NCT00112645</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Pediatric Solid Tumors With Relapsed or Therapy Refractory Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: A peripheral stem cell, bone marrow, or umbilical cord blood transplant may be
      able to replace blood-forming cells that were destroyed by chemotherapy and radiation
      therapy. Sometimes the transplanted cells from a donor can make an immune response against
      the body's normal cells. Giving busulfan and melphalan with or without antithymocyte globulin
      before transplant and cyclosporine with methylprednisolone or methotrexate after transplant
      may stop this from happening.

      PURPOSE: This phase I trial is studying the side effects of donor stem cell transplant in
      treating young patients with relapsed or refractory solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the toxicity of allogeneic hematopoietic stem cell transplantation, in terms
           of the incidence of grade 3-4 acute graft-versus-host disease, in young patients with
           relapsed or refractory solid tumors.

        -  Determine the incidence of transplant-related mortality at 100 days post-transplantation
           in these patients.

      OUTLINE:

        -  Conditioning: Patients receive busulfan IV or orally 4 times daily on days -8 to -5 (a
           total of 16 doses) and melphalan IV over 15-20 minutes on days -4 to -2. Patients with
           an unrelated donor also receive anti-thymocyte globulin IV on days -4 to -2.

        -  Allogeneic hematopoietic stem cell transplantation (SCT): Patients undergo allogeneic
           hematopoietic SCT on day 0.

        -  Post-transplant graft-versus-host disease (GVHD) prophylaxis: Patients who undergo cord
           blood SCT receive cyclosporine and methylprednisolone for graft-versus-host disease
           (GVHD) prophylaxis. Patients who undergo peripheral blood or bone marrow SCT receive
           cyclosporine and methotrexate (short course) for GVHD prophylaxis.

      After completion of study treatment, patients are followed at 1, 3, 6, and 12 months and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Neuroblastoma</condition>
  <condition>Sarcoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of relapsed or refractory solid tumor, including, but not limited to,
             relapsed neuroblastoma, relapsed Ewing's sarcoma, and relapsed rhabdomyosarcoma

          -  No isolated local disease recurrence at the site of the primary tumor &gt; 1 year after
             completion of prior therapy

          -  No brain tumor or brain metastases

          -  Related or unrelated hematopoietic stem cell donor available, meeting 1 of the
             following criteria:

               -  Matched for HLA-A, -B, -C, -DR, and -DQ (9/10 or 10/10 allelles) (marrow or
                  peripheral blood)

               -  Matched for HLA-A, -B, and -DR (5/6 or 6/6 allelles) (cord blood)

                    -  Cord blood specimen must contain ≥ 2 x 10 ^7 nucleated cells/kg body weight

        PATIENT CHARACTERISTICS:

        Age

          -  30 and under

        Performance status

          -  ECOG 0-1 OR

          -  Lansky 80-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Bilirubin ≤ 3.0 mg/dL

        Renal

          -  Creatinine clearance ≥ 50 mL/min

        Cardiovascular

          -  Ejection fraction ≥ 50%

        Pulmonary

          -  DLCO ≥ 70% OR

          -  O_2 saturation ≥ 95% on room air

        Other

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Prior autologous stem cell transplantation allowed

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth G. Lucas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

